Extended Evaluation of Recombinant Human Activated Protein C United States Trial (ENHANCE US)
- 1 June 2004
- journal article
- clinical trial
- Published by Elsevier BV in Social psychiatry. Sozialpsychiatrie. Psychiatrie sociale
- Vol. 125 (6), 2206-2216
- https://doi.org/10.1378/chest.125.6.2206
Abstract
No abstract availableThis publication has 22 references indexed in Scilit:
- Drotrecogin Alfa (Activated) Treatment of Older Patients with Severe SepsisClinical Infectious Diseases, 2003
- The Epidemiology of Sepsis in the United States from 1979 through 2000The New England Journal of Medicine, 2003
- Efficacy and safety of LY315920Na/S-5920, a selective inhibitor of 14-kDa group IIA secretory phospholipase A2, in patients with suspected sepsis and organ failureCritical Care Medicine, 2003
- Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsisCritical Care Medicine, 2003
- Assessing the Use of Activated Protein C in the Treatment of Severe SepsisThe New England Journal of Medicine, 2002
- Randomized Trials or Observational Tribulations?The New England Journal of Medicine, 2000
- Randomized, Controlled Trials, Observational Studies, and the Hierarchy of Research DesignsThe New England Journal of Medicine, 2000
- A Comparison of Observational Studies and Randomized, Controlled TrialsThe New England Journal of Medicine, 2000
- The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failureIntensive Care Medicine, 1996
- APACHE IICritical Care Medicine, 1985